Inflammation, atherosclerosis, and stroke

Neurologist

Volumn 12, Issue 3, 2006, Pages 140-148

  Elkind, Mitchell S V ^a,b,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Atherosclerosis; Inflammation; Risk factors; Statins; Stroke

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; PRAVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ATHEROSCLEROSIS; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; HIGH RISK PATIENT; HUMAN; INFLAMMATION; MALE; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE; STROKE PATIENT;

ANTIGENS, CD; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; CYTOKINES; DIFFUSION MAGNETIC RESONANCE IMAGING; HOMOCYSTEINE; HUMANS; INFLAMMATION; INTERNAL CAPSULE; INTRACRANIAL ARTERIOSCLEROSIS; RISK FACTORS;

EID: 33646801225     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000215789.70804.b0     Document Type: Review

References (73)

1. 1a. Virchow R, Reinhardt B. Archiv für Pathologische Anatomie und Physiologie and für Klinische Medicin. Berlin: Bruck und Verlag von G. Reimer; 1847.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
3. Munro JM, van der Walt JD, Munro CS, et al. An immunohistochemical analysis of human aortic fatty streaks. Hum Pathol. 1987;18:375-380.
4. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89:2462-2478.
5. van der Wal AC, Das PK, Bentz van de Berg D, et al. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest. 1989;61:166-170.
6. Nilsson J. Cytokines and smooth muscle cells in atherosclerosis. Cardiovasc Res. 1993;27:1184-1190.
7. Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature. 1990;344:254-257.
8. Chappell DC, Varner SE, Nerem RM, et al. Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. Circ Res. 1998;82:532-539.
9. Iiyama K, Hajra L, Iiyama M, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res. 1999;85:199-207.
10. Nagel T, Resnick N, Atkinson WJ, et al. Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. J Clin Invest. 1994;94:885-891.
11. Lin MC, Almus-Jacobs F, Chen HH, et al. Shear stress induction of the tissue factor gene. J Clin Invest. 1997;99:737-744.
12. Kim CJ, Khoo JC, Gillotte-Taylor K, et al. Polymerase chain reaction-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tumor necrosis factor alpha and interleukin-1beta. Arterioscler Thromb Vasc Biol. 2000;20: 1976-1982.
13. Hynes RO, Wagner DD. Genetic manipulation of vascular adhesion molecules in mice. J Clin Invest. 1996;98:2193-2195.
14. Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200-203.
15. De Caterina R, Basta G, Lazzerini G, et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:2646-2654.
16. Hwang S-J, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997;96:4219-4225.
17. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol. 1997;17:1859-1867.
18. Schonbeck U, Mach F, Sukhova GK, et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res. 1997;81:448-454.
19. Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33-43.
20. Tenaglia AN, Buda AJ, Wilkins RG, et al. Levels of expression of P-selectin, E-selectin, and intercellular adhesion molecule-1 in coronary atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol. 1997;79:742-747.
21. Simon AD, Yazdani S, Wang W, et al. Inflammatory cytokine profiles in stable versus unstable angina. J Thromb Thrombolysis. 2000;9:217-222.
22. Jander S, Sitzer M, Schumann R, et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke. 1998;29:1625-1630.
23. DeGraba TJ, Siren AL, Penix L, et al. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke. 1998;29:1405-1410.
24. DeGraba TJ. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology. 1997;49(5 suppl 4):S15-19.
25. Falkenberg M, Bjornheden T, Oden A, et al. Heterogeneous distribution of macrophages, tumour necrosis factor alpha, tissue factor and fibrinolytic regulators in atherosclerotic vessels. Eur J Vasc Endovasc Surgery. 1998;16:276-283.
26. Elkind MS, Cheng J, Boden-Albala B, et al. Elevated white blood cell count and carotid plaque thickness: the Northern Manhattan Stroke Study. Stroke. 2001;32:842-849.
27. Salonen R, Salonen JT. Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. Atherosclerosis. 1990;81:33-40.
28. Yarnell JWG, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation. 1991;83:836-844.
29. Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease: insights from the Framingham Study. JAMA. 1992;267:1253-1256.
30. Grau AJ, Buggle F, Becher H, et al. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Res. 1996;82:245-255.
31. Prentice RL, Szatrowski TP, Kato H, et al. Leukocyte counts and cerebrovascular disease. J Chronic Dis. 1982;35:703-714.
32. Elkind MSV, Sciacca R, Boden-Albala B, et al. Relative elevation in leukocyte count predicts first cerebral infarction. Neurology. 2005;64: 2121-2125.
33. Verma S, Szmitko PE, Yeh ETH. C-reactive protein: structure affects function. Circulation. 2004;109:1914-1917.
34. Khreiss T, Joszef L, Potempa LA, et al. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation. 2004;109:2016-2022.
35. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
36. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
37. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
38. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
39. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-2011.
40. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127.
41. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
42. Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol. 2000;20:1052-1056.
43. Gussekloo J, Schaap MC, Frolich M, et al. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol. 2000;20:1047-1051.
44. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. Stroke. 2001;32:2575-2579.
45. Curb JD, Abbott RD, Rodriguez BL, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation. 2003;107:2016-2020.
46. Cao JJ, Thach C, Manolio TA, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108:166-170.
47. Packard CJ, O'Reilly DSJ, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148-1155.
48. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2004; 109:837-842.
49. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005; 111:570-575.
50. Liuzzo G, Kopecky SL, Frye RL, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation. 1999;100:2135-2139.
51. Nadareishvili ZG, Li H, Wright V, et al. Elevated pro-inflammatory CD4+CD28- lymphocytes and stroke recurrence and death. Neurology. 2004;63:1446-1451.
52. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149-2153.
53. Biasucci LN, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;2079-2084.
54. Biasucci LN, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94:874-877.
55. Kanda T, Hirao Y, Oshima S, et al. Interleukin-8 as a sensitive marker of unstable coronary artery disease. Am J Cardiol. 1996;77: 304-307.
56. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99:855-860.
57. Beamer NB, Coull BM, Clark WM, et al. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol. 1995;37:800-805.
58. Vila N, Castillo J, Davalos A, et al. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31: 2325-2329.
59. Muir KW, Weir CJ, Alwan W, et al. C-reactive protein and outcome after ischemic stroke. Stroke. 1999;30:981-985.
60. Arenillas JF, Alvarez-Sabin J, Molina CA, et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke. 2003;34:2463-2470.
61. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001;32:133-138.
62. Winbeck K, Poppert H, Etgen T, et al. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke. 2002;33:2459-2464.
63. Grundy S, Cleeman J, Merz C, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-239.
64. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 2002;324:1570-1576.
65. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 88:672-674.
66. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-1111.
67. Garlichs CD, Kozina S, Fateh-Moghadam S, et al. Upregulation of CD40-CD40 Ligand (CD154) in patients with acute cerebral ischemia. Stroke. 2003;34:1412-1418.
68. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:91-93.
69. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191-1193.
70. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
71. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
72. Pearson TA, Mensah GA, Hong Y, et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: overview. Circulation. 2004;110:e543-544.
73. Wolf PA, Clagett GP, Easton JD, et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 1999;30:1991-1994.